LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Akciju saraksts・MannKind Corp

MannKind Corp

Atvērts

SektorsVeselības aprūpe

3.51 4.46

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.38

Max

3.5300000000000002

Galvenie mērījumi
By Trading Economics
Ienākumi	-671K -17M
Pārdošana	-22M 90M
P/E Sektora vidējais	140.5 49.701
EPS	-0.02
Peļņas marža	-18.431
Darbinieki	591
EBITDA	5.9M 3.4M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+123.08% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	56M 924M
Iepriekšējā atvēršanas cena	-0.95
Iepriekšējā slēgšanas cena	3.51

Ziņu noskaņojums

By Acuity

50%

159 / 345 Rangs Healthcare

MannKind Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. maijs 08:24 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026. g. 25. maijs 21:22 UTC

Peļņas

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026. g. 25. maijs 20:50 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:20 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:01 UTC

Tirgus saruna

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026. g. 25. maijs 14:43 UTC

Tirgus saruna

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026. g. 25. maijs 14:15 UTC

Tirgus saruna

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026. g. 25. maijs 13:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 25. maijs 12:58 UTC

Tirgus saruna

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026. g. 25. maijs 12:56 UTC

Tirgus saruna

Peļņas

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 25. maijs 12:34 UTC

Tirgus saruna

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026. g. 25. maijs 12:10 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero's Assets Look Strategic -- Market Talk

2026. g. 25. maijs 11:00 UTC

Tirgus saruna

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026. g. 25. maijs 10:19 UTC

Tirgus saruna

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026. g. 25. maijs 10:05 UTC

Peļņas

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026. g. 25. maijs 10:04 UTC

Peļņas

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026. g. 25. maijs 10:03 UTC

Peļņas

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026. g. 25. maijs 10:02 UTC

Peļņas

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026. g. 25. maijs 10:01 UTC

Peļņas

Tenaga Nasional 1Q Net Up 3.7% on Year

2026. g. 25. maijs 10:00 UTC

Peļņas

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q EPS MYR0.1883

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Rev MYR17.1B

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Net MYR1.1B

2026. g. 25. maijs 09:38 UTC

Tirgus saruna

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026. g. 25. maijs 08:55 UTC

Tirgus saruna

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Salīdzinājums

Cenas izmaiņa

MannKind Corp Prognoze

Cenas mērķis

By TipRanks

123.08% augšup

Prognoze 12 mēnešiem

Vidējais 7.54 USD 123.08%

Augstākais 10 USD

Zemākais 4.75 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MannKind Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam MannKind Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

159 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.